Related Experiment Video
Updated: Nov 12, 2025
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Chimeric Antigen Receptor T Cells for Multiple Myeloma: The Journey So Far-And the Road Ahead
Abstract:
Despite improvements in effective therapy, multiple myeloma remains incurable, and virtually all patients will face relapsed disease at some point after diagnosis. The prognosis for relapsed myeloma after developing resistance to anti-CD38 monoclonal antibodies, proteasome inhibitors, immunomodulatory agents, and autologous stem cell transplantation has been poor; however, the development of immune effector cell therapy with chimeric antigen receptor (CAR) T cells may dramatically improve the outlook for patients, although none of these therapies are approved for MM to date. Herein, we review the development and history of CAR T-cell therapy for multiple myeloma, mechanisms of resistance, and strategies to improve outcomes with CAR T therapy.
Insights
Multiple myeloma remains incurable, but chimeric antigen receptor (CAR) T-cell therapy offers new hope for relapsed patients. This review explores CAR T-cell therapy development, resistance, and strategies to enhance outcomes in multiple myeloma.
Area of Science:
- Oncology
- Immunotherapy
- Hematology
Background:
- Multiple myeloma is an incurable blood cancer with a high rate of relapse.
- Existing therapies including anti-CD38 antibodies, proteasome inhibitors, immunomodulatory agents, and stem cell transplantation eventually fail in most patients.
- The prognosis for patients with relapsed or refractory multiple myeloma is historically poor.
Purpose of the Study:
- To review the development and history of chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
- To discuss mechanisms of resistance to CAR T-cell therapy in multiple myeloma.
- To outline strategies for improving outcomes with CAR T-cell therapy in multiple myeloma.
Main Methods:
- Literature review of CAR T-cell therapy in multiple myeloma.
- Analysis of resistance mechanisms.
- Synthesis of strategies to improve CAR T-cell therapy efficacy.
Main Results:
- CAR T-cell therapy represents a promising new frontier for relapsed/refractory multiple myeloma.
- Understanding resistance mechanisms is crucial for optimizing CAR T-cell therapy.
- Ongoing research focuses on overcoming resistance and enhancing CAR T-cell therapy effectiveness.
Conclusions:
- Chimeric antigen receptor (CAR) T-cell therapy holds significant potential to improve outcomes for patients with relapsed multiple myeloma.
- Further research into resistance mechanisms and novel therapeutic strategies is essential for maximizing the benefit of CAR T-cell therapy.
- While not yet approved, CAR T-cell therapy is a rapidly evolving field with the potential to transform multiple myeloma treatment.
